2012-09-17 06:10:55 - Recently published research from Global Markets Direct, "Systemic Lupus Erythematosus - Pipeline Review, H2 2012", is now available at Fast Market Research
Global Markets Direct's, 'Systemic Lupus Erythematosus - Pipeline Review, H2 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. 'Systemic Lupus Erythematosus - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/463851_systemic_lupus_erythematosus_pipeline ..
Note*: Certain sections in
the report may be removed or altered based on the availability and relevance of data for the indicated disease.
* A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus.
* A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Systemic Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Systemic Lupus Erythematosus therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Systemic Lupus Erythematosus Therapeutic Products under Development, Key Players in Systemic Lupus Erythematosus Therapeutics, Systemic Lupus Erythematosus Pipeline Overview, Systemic Lupus Erythematosus Pipeline, Systemic Lupus Erythematosus Pipeline Assessment
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Systemic Lupus Erythematosus Overview
An Overview of Pipeline Products for Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Therapeutics under Development by Companies
Systemic Lupus Erythematosus Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Systemic Lupus Erythematosus Therapeutics - Products under Development by Companies
Systemic Lupus Erythematosus Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Systemic Lupus Erythematosus Therapeutics Development
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
AbGenomics International, Inc.
Human Genome Sciences, Inc.
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Onyx Pharmaceuticals, Inc.
Genesis Research and Development Corporation Ltd.
Hollis-Eden Pharmaceuticals, Inc.
Active Biotech AB
Idera Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Dynavax Technologies Corporation
Shenzhen Beike Biotechnology Co., Ltd.
Argos Therapeutics, Inc.
Astion Pharma A/S
Theraclone Sciences, Inc.
Trillium Therapeutics Inc.
Anthera Pharmaceuticals, Inc.
KYORIN Pharmaceutical Co., Ltd.
Zenyaku Kogyo Co., Ltd.
Systemic Lupus Erythematosus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Laquinimod - Drug Profile
Lupuzor - Drug Profile
AMG 811 - Drug Profile
AMG 557 - Drug Profile
Atacicept - Drug Profile
Rontalizumab - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.